
Lilly and Stipple Bio Sign Oncology Deal
Eli Lilly has partnered with Stipple Bio in an oncology research agreement worth up to $5.9 billion. The deal provides Lilly access to technology designed to target cancer cells.
Xurve View
Insights:
Xurve View

Eli Lilly & Co signed an oncology research collaboration and licensing agreement worth up to $5.9 billion with Stipple Bio on Monday. The partnership gives Lilly access to technology designed to identify molecules that distinguish cancer cells from healthy tissue. The deal expands Lilly's oncology pipeline beyond its blockbuster diabetes and obesity treatments.









